Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
Yaseen M. Arabi
, Ali H. Hajeer, Thomas Luke, Kanakatte Raviprakash, Hanan Balkhy, Sameera Johani, Abdulaziz Al-Dawood, Saad Al-Qahtani, Awad Al-Omari, Fahad Al-Hameed, Frederick G. Hayden1
, Robert Fowler, Abderrezak Bouchama, Nahoko Shindo, Khalid Al-Khairy, Gail Carson, Yusri Taha, Musharaf Sadat, and Mashail Alahmadi
Author affiliations: King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M. Arabi, A.H. Hajeer , H. Balkhy, S. Johani, A. Al-Dawood, S. Al-Qahtani, A. Bouchama, K. Al-Khairy, M. Sadat, M. Alahmadi); Naval Medical Research Center, Silver Spring, Maryland, USA (T. Luke, K. Raviprakash); Alfaisal University, Riyadh (A. Al-Omari); King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia (F. Al-Hameed); University of Virginia School of Medicine, Charlottesville, Virginia, USA (F.G. Hayden); University of Toronto, Toronto, Ontario, Canada (R. Fowler); World Health Organization, Geneva, Switzerland (N. Shindo); University of Oxford Centre for Tropical Medicine, Oxford, UK (G. Carson); King Abdulaziz Medical City, Al-Ahsa, Saudi Arabia (Y. Taha)
Figure 3. Correlation between ELISA optical density and antibody assay results in a study determining the feasibility of using convalescent plasma immunotherapy for Middle East respiratory coronavirus infection, Saudi Arabia. A) Correlation between ELISA and microneutralization assay results (Pearson correlation coefficient 0.70, p = 0.001). B) Correlation between ELISA and indirect immunofluorescent antibody (IFA) assay results (Pearson correlation coefficient 0.55, p = 0.015). C) Correlation between IFA and microneutralization assay results. (Pearson correlation coefficient 0.38, p = 0.12).
Page created: August 16, 2016
Page updated: August 16, 2016
Page reviewed: August 16, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.